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Abstract
In liver cirrhosis, portal vein thrombosis (PVT), which is defined as thrombosis that 
occurs within the main portal vein and intrahepatic portal branches, is one of the most 
common complications. High incidence of PVT in the setting of liver cirrhosis is mainly 
due to hypercoagulable state and altered dynamic of blood flow in the portal vein. The 
clinical manifestations of PVT are variable among different patients, so the diagnosis 
of PVT is mainly dependent on the imaging examinations, like ultrasound, computed 
tomography and magnetic resonance imaging. The overall goal of treatment for PVT 
can be summarized as reducing risk factors of PVT, thus to prevent further expansion of 
thrombus and maintain portal patency and prevent and treat the symptoms of PVT by 
anticoagulants, local thrombolysis, transjugular intrahepatic portosystemic shunt and/
or surgery. In future, due to the progress in vascular imaging and innovation in clinical 
anti-thrombotic drug, PVT could be prevented and cured effectively.
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1. Introduction
Portal vein thrombosis (PVT) is diagnosed when a venous thrombosis occurs within the main 
portal vein and intrahepatic portal branches [1, 2]. In liver cirrhosis, especially in advanced 
stages, PVT is one of the most common complications [3–5]. High incidence of PVT in the set-
ting of liver cirrhosis is mainly due to hypercoagulable state and altered dynamics of blood 
flow in the portal vein [6–8]. Moreover, PVT will deteriorate liver cirrhosis by increasing por-
tal vein pressure and decreasing blood flow into liver. Under severe circumstances, it will 
worsen symptoms of cirrhosis such as ascites, upper gastrointestinal bleeding, intestinal avas-
cular necrosis and so on [3, 4, 9–11]. However, 30–50% patients with PVT will spontaneously 
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alleviate or recover without any treatment [4, 10, 12, 13]. This highlights the over-diagnosis 
of PVT in cirrhosis and questions whether PVT treatment will benefit cirrhotic patients, espe-
cially when they are diagnosed incidentally on imaging. Right now, there is no guideline 
or expert consensus on how to manage cirrhotic patients with PVT. A meta-analysis which 
includes 3735 cirrhotic patients demonstrated that PVT negatively influenced both mortality 
and hepatic decompensation, despite its limitation of including heterogeneous populations 
[14]. However, another prospective multicenter study which includes 863 Child-Pugh class A 
and 380 class B cirrhotic patients found PVT was not a prognostic factor for either mortality or 
hepatic decompensation [15]. A study that only investigated 42 cirrhotic patients with extra-
hepatic nonmalignant partial PVT reported that no association was found between progres-
sion or regression of partial PVT and clinical outcomes. The model for end-stage liver disease 
(MELD) score, rather than PVT, was the predictor of worse prognosis in cirrhotic patients [16]. 
So, at present, the issue of whether PVT does or does not have influence on the natural history 
of cirrhosis is still controversial [17–19].
2. Prevalence
The prevalence and incidence of PVT in cirrhosis often varies from 1 to 28% among different stud-
ies depending on heterogeneity in diagnosis methods, different populations and variable follow-
up time [16–22]. In a retrospective study of 150 patients with viral cirrhosis, the cumulative overall 
incidences of PVT were 12.8% at 1 year, 18.6% at 3 years, 20% at 5 years and 38.7% at 8–10 years, 
respectively [23]. In another study, which includes 701 cirrhosis patients without hepatocellular 
carcinoma, the incidence of PVT was 11.2% since they used ultrasound for diagnosis routinely [24]. 
PVT is more common in advanced cirrhosis and the incidence is positively related with the stage 
of cirrhosis, which is only 1% in compensated patients but 8.4% in severe cirrhosis waiting for 
liver transplantation [21, 25–28]. However, there are some limitations in these studies which 
weaken the magnitude and reliability of these conclusions like different subgroup patients and 
follow-up times as we previously mentioned. Violi et al. reported a study aimed at evaluating the 
prevalence of PVT in a broad spectrum of patients with cirrhosis and found 17% of 753 cirrhotic 
patients had PVT [29]. A multicenter randomized trial that includes 898 well-compensated cir-
rhosis patients reported that the 5-year cumulative incidence of PVT was 11.9% [30].
3. Pathophysiology
3.1. Hypercoagulable state of blood flow
After liver transplantation, the number of platelets will increase temporarily for a short time, 
which contributes to the hypercoagulable state of blood [31, 32]. That would be one of the 
significant reasons for PVT formation in liver transplantation patients. The study showed 
that surgery not only increased blood platelets but also activated their surface glycoprotein 
CD62P, reflecting the degree of platelet activation and causing a hypercoagulable state [33, 34]. 
Postoperative-elevated CD62P is closely related with PVT, which can be used as a sensitive 
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diagnostic biomarker of PVT [9, 35, 36]. Toshiki Matsui also reported that soluble form of gly-
coprotein VI, as a platelet activation marker, was associated with PVT formation after hepa-
tectomy and splenectomy in patients with liver cirrhosis [37]. Another study from Poland 
found platelet aggregability was decreased in PVT patients [31]. In another logistic regression 
model, incidence of PVT was highly related with D-dimer and bilirubin [38, 39]. Additionally, 
increased whole blood viscosity due to increased number of erythrocytes and ability of aggre-
gation as well as decreased deformability may be reasons for increased PVT formation [34, 
40]. Both procoagulant and anticoagulant proteins decreased in liver cirrhosis patients at the 
same time, owing to decreased synthesis function of the liver, which often largely maintained 
in a dynamic balance [7, 8, 34, 41]. Therefore, the body is neither to bleed nor to form thrombo-
sis. However, after liver transplantation surgery, venous injury would reduce the flow rate of 
portal vein; thus, anticoagulant-associated protein S and C decreased as well as anti-thrombin 
III [21]. Meanwhile, surgery consumes numerous coagulation factors. Factor VIII, VII factor-
related antigens and anti-cardiolipin antibody increased, which both resulted in PVT forma-
tion. Factor VIII concentration and the ratio of the most powerful procoagulant (factor VIII) 
and anticoagulant (protein C) were considered as markers to indicate hypercoagulability [25, 
38, 42–44]. Studies showed factor VIII was related to PVT in cirrhotic patients independently. 
Patients with factor VIII level above 129 IU/dl had six times the probability to PVT [45]. Some 
researchers reported in the literature that procoagulant gene mutations, including coagula-
tion factor V Leiden G1691A, methylenetetrahydrofolate reductase C677T and prothrombin 
G20210A, may be associated with PVT [46, 47]. Recent studies showed that increased hem-
agglutinin activated fibrinolysin inhibition gene mutation and blood coagulation factor VII, 
which were closely related to the occurrence of PVT [1, 2].
3.2. Hemodynamic changes in the portal vein
PVT formation is associated with intrahepatic resistance and poor portal blood flow. 
Moreover, portal blood flow decreases more if cirrhosis progresses. That’s why the incidence 
of PVT is much higher in advanced-stage cirrhotic patients compared with well-compensated 
ones [48]. Cirrhotic patients with PVT had low portal flow volumes and high collateral vessel 
flow velocity. Intraoperative clamp and squeeze will cause vein intimal injury, collagen expo-
sure and activation of the coagulation system. After liver transplantation, blood flow in portal 
vein is relatively slow, which is easy to form turbulence and thrombosis [9, 25, 49, 50]. Portal 
vein blood flow velocity and PVT have an important relationship. Studies demonstrated that 
patients with portal vein blood flow <15 cm/s had higher incidence of PVT [17, 27, 50–52]. So, 
some researchers often regarded portal vein diameter as an independent risk factor for the 
formation of PVT. In short, because there are various changes in portal hemodynamics, the 
incidence of PVT is quite high after liver transplantation.
3.3. Endotoxinemia
Cirrhosis is more likely to damage intestinal mucosal barrier which facilitates bacterial trans-
location and endotoxinemia [53]. Endotoxinemia not only can increase portal vein pressure 
but also can activate coagulation cascade. That explains why it can increase the PVT incidence 
in the portal system [54].
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4. Diagnosis
4.1. Clinical manifestations
A study which includes 79 cirrhotic patients has shown that 57% of PVT were symptomatic and 
among them 39% had gastrointestinal bleeding and 70% had intestinal infarction [24]. Abdominal 
pain is generally the earliest clinical symptom after the acute formation of PVT. Usually, 
abdominal pain is limited within a specific region while few are diffuse pain and intermittent 
colic pain with longer durations. Nausea and vomiting occur in 50% of PVT patients [3, 4, 51, 
55–57]. A few patients will have diarrhea or bloody stool. If complete intestinal obstruction 
occurs suddenly, abdominal pain is paroxysmal accompanied by significant nausea, vomiting 
without fart and defecation. Under this circumstance, there are no obvious physical examina-
tion signs, that the degree of pain is not consistent with the signs of the abdomen [19, 58, 59]. 
Increased anterior hepatic obstructive factors will cause decreased portal vein blood flow 
which aggravates liver damage, increases portal pressure, causes repeated upper gastrointes-
tinal bleeding and refractory ascites and so on. In some severe cases, clinical manifestations 
of intestinal necrosis such as persistent abdominal pain, bloating, hemafecia, hematemesis, 
shock and peritoneal irritation will occur [18, 24, 26]. Abdominal puncture can be bloody asci-
tes. In the event of intestinal necrosis, disease mortality rate can rise to 20–60%. Patients often 
suffer from persistent abdominal pain, hemafecia, abdominal cramps, ascites, multiple organ 
failure and so on. For chronic PVT, patients will have refractory bloating, diarrhea, upper 
abdominal pain and ascites due to gastrointestinal congestion and insufficient perfusion of 
liver portal vein [24]. The clinical manifestations of PVT are variable among different patients, 
so the clinical diagnosis of PVT is mainly dependent on the imaging examination.
4.2. Imaging
Ultrasound, the most common imaging way, is simple and easy to accurately evaluate PVT [60]. 
Thus, it is the preferred imaging method for diagnosis. Ultrasound diagnosis of PVT 
is characterized by abnormal echo in the portal vein, unclear boundary with the wall, 
CDFI: no blood flow signal, portal venous cavernous hemangioma; portal vein expansion 
before thrombosis site; and no display of portal vein if PVT is formed within a wide range 
[11, 17, 18, 60, 61]. The sensitivity and specificity of ultrasonography to diagnose PVT are up 
to 60 and 100% [60, 62]. Ultrasound can clearly demonstrate the blood flow, vascular diameter 
and the changes and the presence of thrombi. Ultrasound can also determine the formation of 
collateral circulation simultaneously through CDFI. But the ultrasound cannot reflect directly 
the situation of the portal vein and its branches, and the experience of the operator affects the 
accuracy of the diagnosis. Ultrasound angiography or ultrasound endoscopy can diagnose 
PVT more accurately that even raises the diagnostic sensitivity to 81% [24]. Some authors 
recommended contrasting enhanced ultrasound as the first-line imaging and “gold standard 
method” for the diagnosis of PVT [63, 64]. But ultrasound angiography and endoscopy also 
have some limitations. Firstly, they cannot evaluate the portal vein within the part of the liver 
and superior mesenteric vein end accurately. Moreover, they cannot assess the surrounding 
organs which may be affected by PVT [50, 63, 64].
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Enhanced computer tomography (CT) or enhanced magnetic resonance imaging (MRI) exam-
ination by intravenous injection contrast can effectively solve the above deficiencies. By com-
parison with contrast, we can discover intraluminal filling defects and perfusion conditions 
for nearby organs at different times of the imaging process. CT angiography (CTA) and mag-
netic resonance angiography (MRA) greatly increase the accuracy of diagnosis. Some studies 
have showed that the sensitivity and the specificity for CTA were 86 and 95%. For MRA, 
the sensitivity was 100% and specificity was 98% [60, 65–67]. Typical CT signs of PVT are 
very intuitive: no-enhanced low-density intraluminal stripe or massive lesions within portal 
static. Occasionally, CT can also find an enhanced ring around thrombus due to nourishing 
small blood vessels. Moreover, CT can also help to diagnose primary liver cancer, cirrhosis 
and evaluate intestinal ischemia and necrosis. CTA has several advantages including short 
scan time, fast imaging speed and reduced motion artifact [67]. However, its main drawbacks 
can be related to some complications like contrast agent allergy, contrast agent nephropathy 
and other adverse reactions. The safety of MRA contract is significantly better than that of 
CTA. But MRA has the same disadvantages like motion artifacts, long-signal acquisition time 
and limited imaging range [66]. Therefore, patients with suspicious PVT should be enrolled in 
contract CT or MRI imaging, which can be more accurate for clinical diagnosis.
Angiography is the traditional method for diagnosis of PVT. It is not the routine examination of 
PVT because of its invasive feature. Angiography includes two categories: indirect and direct. 
Indirect angiography is through splenic artery and superior mesenteric artery to image [2, 65]. 
In this way, we can see the portal vein filling defect as well as the collateral circulation. The most 
important thing is we can put the catheter into the superior mesenteric artery and/or splenic 
artery branch to infuse thrombolytic drugs after indirect angiography. It means we can finish 
diagnosis and follow treatment after invasive process at one time. Direct angiography is divided 
into: percutaneous transhepatic portal angiography, which can display directly portal vein sys-
tem and evaluate portal hemodynamics, and umbilical portal vein angiography, which is indi-
cated for splenic vein thrombosis, spleen resection and failure of arterial portal angiography [50].
4.3. Laboratory tests
Usually, prothrombin time (PT) and activated partial thromboplastin time (APTT) were used 
as predictors for the coagulation state with cirrhosis, and even the predictive ability was poor 
[7, 34, 68]. Because they could not explain and represent natural anticoagulants such as anti-
thrombin and protein C in vivo, the thrombin generation test, which used tissue factor as 
trigger and phospholipids as platelet substitutes, was considered more appropriate for evalu-
ating thrombin generation. The test was regarded as representation of the balance between 
the pro- and anticoagulant proteins in plasma [33, 44]. Another test named thromboelastog-
raphy (TEG) can monitor all kinds of hemostatic functions (coagulation, anticoagulation, 
fibrinolysis) continuously to predict thrombosis formation and dissolution dynamically. This 
test also emphasized the dynamic assessment of balanced status in blood coagulation and 
anticoagulation process [17, 18]. This is a new laboratory test to evaluate whether the blood 
is hypercoagulable, whether there is the formation of thrombus and whether the thrombus is 
stable. The effectiveness of clinical application needs to be further studied. Additionally, we 
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can exclude PVT patients with a 90% negative predictive value when the D-dimer level is less 
than 1.82 mg/l [38, 39, 69, 70]. Systemic evaluation of coagulation tests, including PT, interna-
tional standardization ratio, partial thromboplastin time, and so on, could not fully assess the 
patient’s coagulation abnormalities. Dynamic monitoring of vitamin K-related coagulation 
factors, fibrinogen, platelet function, fibrinolysis status as well as other coagulation factors 
simultaneously is essential.
5. Classification
According to PVT imaging findings preoperatively, Yerdel found a classification system as 
the following: grade I, <50% portal vein obstruction with or without micro-thrombus of the 
superior mesenteric vein; grade II, >50% portal vein obstruction with or without micro-throm-
bus of the superior mesenteric vein; grade III, complete portal vein and proximal superior 
mesenteric vein obstruction; and grade IV, complete portal vein and entire superior mesen-
teric vein obstruction [71].
6. PVT treatment
The overall goal of treatment for PVT can be summarized as reducing risk factors of PVT, thus 
to prevent further expansion of thrombus and maintain portal patency, prevent and treat the 
symptoms of PVT. For acute PVT, the aim is to prevent thrombus extension and intestinal 
infarction, whereas for chronic PVT, it is to prevent recurrent thrombosis, gastrointestinal 
bleeding and portal cholangiopathy [20, 35, 51].
6.1. Non-surgical treatment
The incidence of PVT is high in cirrhotic patients, but clinical studies found that 30–50% of 
patients with PVT could alleviate without any treatment. Longest diameter of portal vein 
and blood flow of the largest collateral circulation vein were closely related with the inci-
dence of spontaneous alleviation in PVT patients [1, 21]. But another study demonstrated that 
untreated PVT was associated with increased mortality, especially in patients with low Child-
Pugh scores. And there were strong correlations between anticoagulation therapy and lower 
thrombus progress rate as well as higher recanalization rate [11, 72, 73]. Furthermore, PVT has 
been reported as an independent risk factor for recurrent and refractory acute variceal bleeding 
[23, 74]. There is inconsistent guidance on the anticoagulant management of PVT. However, 
once the PVT is diagnosed, the optimal time of prevention and treatment often has been 
missed. Serious complications would increase mortality greatly for PVT patients. So, it is rec-
ommended for cirrhotic patients that routine color Doppler ultrasound assessment should 
be performed. Early diagnosis, early anticoagulant and thrombolytic therapy can effectively 
improve the prognosis of patients. A meta-analysis from Italy, which includes 8 studies com-
prising 353 patients with cirrhosis and PVT, demonstrated anticoagulant therapy (low-weight 
heparin or warfarin) could increase recanalization and reduce progression of thrombosis 
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effectively [75]. Meanwhile, these anticoagulants will not increase the incidence of any kinds 
of bleedings [75]. Another study from Italy found the benefits patients got overweighed the 
potential minor bleeding risk [76]. And they also concluded that portal hypertension, rather 
than anticoagulants, would be the real reason for the risk of major bleeding among cirrhotic 
patients with PVT. A prospective study from China which focused on patients with cirrhosis 
undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) found that warfarin 
treatment within 12 months achieved a much higher rate of complete recanalization [77]. 
The commonly used drugs include warfarin, low molecular weight heparin and urokinase [78–81]. 
Most patients with acute PVT were recommended early anticoagulant therapy at least for 
6 months. A systematic review and meta-analysis that summarized different regiments of 
anticoagulation has been reported [82]. In this study, the overall rate of portal vein recanaliza-
tion was 37–93% and the anti-coagulation related bleeding was 0–18% [82]. In this way, we 
can not only reduce the incidence of PVT greatly but also increase PVT recanalization rate up 
to 39.3–100.0%.
In recent years, inhibitors of activated factor Xa (e.g., rivaroxaban) have been used in the 
prevention of clinical PVT. The advantages are convenient oral administration, no effect on 
the international standardization ratio and no need to monitor blood coagulation indicators. 
Hyeyoung Yang et al. reported a 63-year-old female who experienced complete resolution of 
recurrent acute PVT in liver cirrhosis after rivaroxaban treatment [83]. The disadvantage is 
there is no effective antagonist. When bleeding happens during anticoagulant therapy, the 
consequence is serious. However, some new oral anticoagulants’ antidotes have been under 
investigation like andexanet alfa, P-glycoprotein substrates and drugs inducing CYP3A4. 
They all could inhibit the concentration or absorption of new oral anticoagulants and attenu-
ate their effects remarkably [83, 84].
In short, clinical non-surgical methods are still mainly treatments of PVT in cirrhotic patients.
6.2. Local thrombolytic treatment
Local thrombolysis is divided into indirect way (femoral artery-superior mesenteric artery 
indwelling catheter thrombolysis) and direct way (percutaneous transhepatic portal vein 
thrombolysis) [13, 17, 18, 27, 35, 56, 85].
The advantages of the femoral artery-superior mesenteric artery catheter thrombolysis are 
simple and relative small trauma. It is just suitable for mild PVT without vascular occlusion. 
Because when PVT is found by this method, portal vein branches are usually in the stenosis or 
occlusion state by obstruction of thrombosis. Most of the drugs we injected for thrombolysis 
cannot reach the site of thrombus effectively. So, indications of this method are limited.
The advantages of the percutaneous transhepatic portal vein thrombolysis method are simple 
and show high success rates. However, we must stop this treatment when the patient has: 
(1) APTT significantly longer; (2) the international standardization ratio > 2; and (3) obvi-
ous abdominal pain, bloating, vomiting, hemafecia, increased puncture-point bleeding, more 
subcutaneous ecchymosis, hemoglobin continuing to decrease, faster heart rate, lower blood 
pressure and other signs of active bleeding.
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6.3. TIPS
When severe PVT happened, thrombus blocked more than 50% lumen or completely blocked, 
anticoagulant therapy was unlikely to recanalization. Under this condition, we can choose 
TIPS. This method has the advantages as the following: the risk of thrombolysis is relatively 
small, and punctures can often reach directly to the thrombus site; at the same time intravas-
cular technology (balloon plasty, stent replacement, thrombectomy and thrombolytic therapy 
surgery) can be applied to achieve the goal of treatment of PVT. A study from China which 
compared transcatheter selective superior mesenteric artery urokinase infusion and TIPS has 
found they were safe and effective for acute symptomatic PVT in cirrhosis [86]. But the opera-
tion was a relative difficult and lethal event as well as severe complications were still possible, 
so it is particularly important to assess the risk-benefit ratio of TIPS preoperatively. At pres-
ent, the TIPS therapy methods for PVT are the following [87–89]:
A. TIPS placement → portosystemic shunt → portal vein recanalization;
B. TIPS placement through percutaneous ways portal vein recanalization;
C. TIPS placement between hepatic vein and collateral vessel → no portal vein recanalization
For cirrhotic patients with refractory variceal bleeding and ascites, TIPS was considered as 
one of the major treatment strategies if the patient did not have PVT. PVT has changed natu-
ral history of liver cirrhosis and affected outcomes. So, in this circumstance, TIPS should be 
recommended with caution. No convincing evidence has been published to verify the supe-
riority of TIPS over traditional anticoagulants. TIPS should only be recommended for severe 
PVT patients although technical difficulty rose sharply when severe PVT was diagnosed [89]. 
That means reliable predictors for PVT progression should be further investigated in future.
6.4. Surgical treatment of PVT
Surgery is relatively high risk. The commonly used methods are (1) PVT excision; (2) portal 
vein stent implantation, mainly aimed to relieve portal vein obstruction; (3) liver transplanta-
tion. During treatment, if the patient has the sustained abdominal pain, abdominal distension 
and other signs of peritonitis, laparotomy exploration should be performed early to prevent 
the occurrence of intestinal necrosis. When intestinal necrosis is diagnosed, intestinal and 
mesangial resections should be performed. At the same time, the intestinal end-to-end anas-
tomosis should be done. Anticoagulation was continued after surgery to prevent thrombus 
reformation.
7. PVT prevention
Kawanaka et al. have shown that anti-thrombin III (AT III) activity and splenic vein diam-
eter were the risk factors of PVT after surgery. Moreover, they used those risk factors to for-
mulate risk stratification system [90]. According to the risk stratification, doctors can decide 
whether to give prevention or not: low risk: AT III activity ≥70% and splenic vein straight 
diameter <10 mm, no preventive treatment; intermediate risk: AT III activity <70% or splenic 
Management of Chronic Liver Diseases - Recent Advances58
vein diameter ≥10 mm, simple AT III prevention treatment; and high risk: splenic vein diam-
eter ≥15 mm or from the liver collateral circulation vein diameter ≥10 mm, AT III, low molecu-
lar weight heparin in conjunction with warfarin [90].
Enoxaparin was found to prevent PVT in advanced cirrhotic patients. Daily subcutaneous 
enoxaparin (4000 IU/day) could significantly reduce incidence of PVT in the short and long 
term [91, 92]. And enoxaparin can also decrease the liver decompensation rate and improve 
survival of patients who received liver transplantation [52, 91, 92].
Surgery on the portal vein system should be gentle and accurate. We should prevent unnec-
essary damage to the vascular endothelium and avoid ligation of chunk tissue. If there is no 
obvious bleeding tendency, surgeons should not use hemostatic after surgery which may 
result in thrombosis (Figure 1).
8. Conclusion
PVT was a clinical rare deep venous thrombosis but highly occurred in liver cirrhotic patients. 
Local or systemic factors alone or in combination make contribution to the formation of 
PVT. In clinical, PVT should be given enough attention due to its severe threat to the patient’s 
Figure 1. Algorithm for the treatment of portal vein thrombosis in liver cirrhosis. Abbreviations: PVT, portal vein 
thrombosis; TIPS, transjugular intrahepatic portosystemic shunt; AT III, anti-thrombin III therapy; LWMH, low-weight 
molecular heparin; *according to Yerdel’s study [68]; # according to Kawanaka’s study [90].
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life and health. The overall treatment principles are early diagnosis, early treatment and pre-
vention combined with treatment. In the future, due to the progress in vascular imaging and 
innovation in clinical anti-thrombotic drug, PVT could be prevented and cured effectively.
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